Open Access
| Issue |
E3S Web Conf.
Volume 271, 2021
2021 2nd International Academic Conference on Energy Conservation, Environmental Protection and Energy Science (ICEPE 2021)
|
|
|---|---|---|
| Article Number | 03035 | |
| Number of page(s) | 4 | |
| Section | Research on Energy Chemistry and Chemical Simulation Performance | |
| DOI | https://doi.org/10.1051/e3sconf/202127103035 | |
| Published online | 15 June 2021 | |
- Kolb, S. J., Kissel, J. T. Spinal muscular atrophy. Neurologic clinics, 33(4), 831–846 (2015). [Google Scholar]
- Figueiredo, M. Comparing SMA Therapies Neither Easy Nor Fair, Clinicians Say. Retrieved January 07, 2021, from https://smanewstoday.com/news-posts/2020/08/21Zc omparing-sma-therapies -neither-easy-nor-fair-clinicians-say/ (2020). [Google Scholar]
- Scoto, M., Finkel, R. S., Mercuri, E., & Muntoni, F. Therapeutic approaches for spinal muscular atrophy (SMA). Gene therapy, 24(9), 514–519 (2017). [Google Scholar]
- Gidaro, T., Servais, L. Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps. Developmental Medicine & Child Neurology, 61(1), 19–24 (2019). [Google Scholar]
- Corey, D. R. Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy. Nature neuroscience, 20(4), 497–499 (2017). [Google Scholar]
- La Roche, H. Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy - Full Text View. Retrieved January 07, 2021, from https://clinicaltrials.gov/ct2/show/NCT02913482 (2016). [Google Scholar]
- Daigl, M., Kotzeva, A., Gorni, K., Evans, R., Hawkins, N., Scott, D., ... Servais, L. Pro12 How Does Risdiplam Compare In Infantile Onset Spinal Muscolar Atrophy (Sma)? Preliminary Indirect Treatment Comparisons Based On Firefish Part 1 Data. Value in Health, 22. doi: 10.1016/jjval.2019.09.2344 (2019).. [Google Scholar]
- Dangouloff, T., Servais, L. Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives. Therapeutics and Clinical Risk Management, Volume 15, 1153–1161. doi: 10.2147/tcrm.s172291 (2019). [CrossRef] [PubMed] [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.